Cephalon Response To NICE Guidance On Advanced Breast Cancer Treatment Published 25 February 2009, UK

News — By on March 13, 2009 at 2:00 am

Liz Hardaker, medical director of Cephalon UK. “We are disappointed and surprised that NICE has not taken this opportunity to distinguish between different forms of anthracycline treatment; specifically the use of liposomal-encapsulated doxorubicin. “Myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women (SmPC).

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback